BIOtech Now
Andrew Segerman
DNA defines who we are. And like anything else, sometimes there are mistakes – mutations in genes that can cause life-lasting conditions. But what if broken genes could be repaired? How many patients could we help in the years ahead? This is the promise and possibility of genome editing.
In 2017, as part of their Human Gene-Editing Initiative, the National Academy of Sciences (NAS) and National Academy of Medicine (NAM) released a consensus study exploring the scientific underpinnings of human gene-editing technologies, their potential applications in biomedical research and medicine, and the clinical, ethical, legal, and social implications of their use.
Join BIO and NAS/NAM on Thursday, February 22, 2018 at 1:30 p.m. ET for a webinar to learn about issues and recommendations discussed in the 2017 NAS/NAM report, breakthroughs and next steps in gene editing of somatic cells, and the regulatory framework for therapies that make use of genome editing.
Key participants in the webinar will include:
- Matthew Porteus, Stanford University (consensus study committee member)
- Sandy Macrae, Sangamo Therapeutics
- Peter Marks, U.S. Food and Drug Administration
Audience Q&A to follow.
Click here to register.
Powered by WPeMatico